Amgen (AMGN) Payables (2016 - 2026)

Amgen has reported Payables over the past 18 years, most recently at $2.9 billion for Q1 2026.

For Q1 2026, Payables rose 21.99% year-over-year to $2.9 billion; the TTM value through Mar 2026 reached $2.9 billion, up 21.99%, while the annual FY2025 figure was $2.4 billion, 24.06% up from the prior year.
Payables for Q1 2026 was $2.9 billion at Amgen, up from $2.4 billion in the prior quarter.
Over five years, Payables peaked at $3.0 billion in Q2 2025 and troughed at $1.2 billion in Q3 2022.
A 5-year average of $1.9 billion and a median of $1.6 billion in 2024 define the central range for Payables.
Biggest five-year swings in Payables: fell 5.92% in 2023 and later skyrocketed 87.05% in 2024.
Year by year, Payables stood at $1.6 billion in 2022, then grew by 1.15% to $1.6 billion in 2023, then rose by 20.0% to $1.9 billion in 2024, then increased by 24.06% to $2.4 billion in 2025, then grew by 24.0% to $2.9 billion in 2026.
Business Quant data shows Payables for AMGN at $2.9 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.8 billion in Q3 2025.

Peer Comparison